Abstracts tagged "Psoriatic arthritis"

Abstract Number: 2509 • 2019 ACR/ARP Annual Meeting
Psoriasis Impact on Patient-Reported Outcomes in Psoriatic Arthritis in a Real-World Setting: Results from the APOPSIS Study
Panagiotis Athanassiou ¹, Athina Theodoridou ², Eftychia Maria Koukli ³, Athanasios Georgountzos ⁴, Panagiotis Vlachoyiannopoulos ⁵, Ioannis Kallitsakis ⁶, Lazaros Sakkas ⁷, Aikaterini Matsouka Dapola ⁸, Souzana Gazi ⁹, Panagiotis Georgiou ¹⁰, Patricia Gorecki ¹¹ and Christos Gkamaloutsos¹², ¹General Hospital of Thessaloniki “Agios Pavlos”, Thessaloniki, Greece, ²Private Practice, Thessaloniki, Greece, ³Private Practice, Kifisia-Athens, Greece, ⁴General Hospital of Athens “G. Gennimatas”, Athens, Greece, ⁵University General Hospital of Athens “Laiko”, Athens, Greece, ⁶Private Practice, Chania, Greece, ⁷University General Hospital of Larissa, Larissa, Greece, ⁸Private Practice, Cholargos-Athens, Greece, ⁹General Hospital of Athens “KAT”, Athens, Greece, ¹⁰General Hospital of Patras “Agios Andreas”, Patras, Greece, ¹¹Janseen-Cilag UK, High Wycombe, United Kingdom, ¹²Janssen-Cilag Pharmaceutical SACI(Greece), Athens, Greece
Background/Purpose: Psoriatic arthritis (PsA) is a chronic progressive inflammatory arthropathy associated with psoriasis (PsO). PsA places a considerable burden, adversely affecting health-related quality of life…
Abstract Number: 2879 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Low-dose IL-2 in Rebuilting Immunity Re-equilibrium of Psoriatic Arthritis Patients
Jia Wang ¹, Yu-fei Hao ², Sheng-xiao Zhang², Quan-run Li ³, Jing-yuan Yang ³, Jia-qian Zhang ¹, Guang-ying Liu ¹, Chong Gao ⁴ and Xiao-feng Li ¹, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China (People's Republic), ²The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China (People's Republic), ³Shanxi Medical University, Taiyuan, China (People's Republic), ⁴Brigham and Women’s Hospital, Harvard Medical School, Boston
Background/Purpose: Psoriatic arthritis (PsA) is a T lymphocytes-mediated inflammatory condition. Although regulatory T cells (Tregs) isolated from blood and psoriatic skin have been showed a…
Abstract Number: 290 • 2019 ACR/ARP Annual Meeting
In Psoriatic Arthritis Patients Considered in Remission by Their Rheumatologist, Can Discordance in Disease Activity Assessment Between Patient and Rheumatologist Be Explained by Residual Inflammation as Measured by Ultrasonographic Examination?
Marie Moly¹, Cédric Lukas ², Jacques Morel ¹, Bernard Combe ³ and Gaël Mouterde ⁴, ¹CHU Montpellier, Montpellier, France, ²Rheumatology department, CHU Montpellier, Univ Montpellier, Montpellier, France, ³CHU Montpellier, Montpellier University, Montpellier, France, ⁴CHU Montpellier and Univ Montpellier, Montpellier, France
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous disease and its assessment is sometimes difficult. Perception of disease activity by patient and physician is frequently discordant…
Abstract Number: 1008 • 2019 ACR/ARP Annual Meeting
C-X-C Motif Chemokine 10 (CXCL10) as a Transcriptomic Biomarker of Psoriatic Arthritis Susceptibility
Fatima Abji¹, Anastasiya Muntyanu ², Remy Pollock ¹, Rohan Machhar ¹, Justine (Yang) Ye ³, Vinod Chandran ⁴ and Dafna Gladman ⁵, ¹Krembil Research Institute, University Health Network, Toronto, Canada, ²University of Toronto, University Health Network, Toronto, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University Health Network, University of Toronto, Toronto, Canada, ⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: We previously identified CXCL10, NOTCH2NL, HAT1, and SETD2 as differentially expressed between psoriasis arthritis (PsA) and psoriasis patients without arthritis (PsC). This study aimed…
Abstract Number: 1204 • 2019 ACR/ARP Annual Meeting
Improvements in Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Intravenous Golimumab, an Anti-TNFα Monoclonal Antibody: 1-Year Results of a Phase III Trial
M. Elaine Husni¹, Diane Harrison ², Elizabeth Hsia ³, Eric K H Chan ², Chenglong Han ², Shelly Kafka ⁴, Kim Hung Lo ², Lilianne Kim ² and Arthur Kavanaugh ⁵, ¹Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²Janssen Research & Development, LLC, Spring House, PA, ³Janssen Research & Development, LLC/University of Pennsylvania, Spring House/Philadelphia, PA, ⁴Janssen Scientific Affairs, LLC, Horsham, PA, ⁵University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: In the randomized, phase 3, GO-VIBRANT study, more patients with psoriatic arthritis (PsA) achieved ACR 20/50/70 after 24 weeks IV treatment with the anti-TNFa…
Abstract Number: 1516 • 2019 ACR/ARP Annual Meeting
Achievement of RAPID3 and cDAPSA Treatment Targets Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psoriatic Arthritis in Subjects Treated with Apremilast
Martin Bergman¹, Yusuf Yazici ², Laura Coates ³, Josef Smolen ⁴, M. Elaine Husni ⁵, Sven Richter ⁶, Lichen Teng ⁶ and Arthur Kavanaugh ⁷, ¹Drexel University College of Medicine, Stockholm, Sweden, ²New York University School of Medicine, New York, ³University of Oxford, Oxford, United Kingdom, ⁴Medical University of Vienna, Vienna, Austria, ⁵Department of Rheumatologic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁶Celgene Corporation, Summit, ⁷University of California, San Diego School of Medicine, La Jolla, CA
Background/Purpose: The Routine Assessment of Patient Index Data 3 (RAPID3) is an outcome measure of disease activity entirely derived from patient self-reported measures (Health Assessment…
Abstract Number: 1776 • 2019 ACR/ARP Annual Meeting
Causal Effect of TNF-α, IL-12p70, IL-17 Levels on the Risk of Psoriatic Arthritis: A Mendelian Randomization Study
Dongze WU¹, Priscilla Wong ¹, Steven H.M. Lam ¹, Isaac T. Cheng ¹, Edmund K. Li ¹, Ling Qin ¹ and Lai-Shan Tam ¹, ¹The Chinese University of Hong Kong, Hong Kong, Hong Kong
Background/Purpose: Biologic agents targeting cytokines including TNF-α, IL-12p70 and IL-17 have been proven to be very effective in treating psoriatic arthritis (PsA). Nonetheless, whether these…
Abstract Number: 2447 • 2019 ACR/ARP Annual Meeting
Characteristics of Psoriasis Patients with Subclinical Signs of Musculoskeletal Involvement Detected by Fluorescence Optical Imaging and Confirmed by MRI-assessment
Michaela Koehm¹, Sarah Ohrndorf ², Tanja Rossmanith ³, Hans-Eckhard Langer ⁴, Marina Backhaus ⁵, Gerd Burmester ⁶, Siegfried Wassenberg ⁷, Benjamin Köhler ⁸, Harald Burkhardt ¹ and Frank Behrens ¹, ¹Rheumatology Goethe-University Frankfurt & Fraunhofer IME-TMP, Frankfurt, Germany, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Fraunhofer IME-TMP, Frankfurt, Germany, ⁴RHIO, Düsseldorf, Germany, ⁵Park-Klinik Weissensee, Berlin, Germany, ⁶Charité—University Medicine Berlin, Berlin, Germany, ⁷Centre of Rheumatology, Ratingen, Germany, ⁸Rheumazentrum Ratingen, Ratingen, Germany
Background/Purpose: Psoriasis (Pso) is one of the most common chronic inflammatory skin diseases in Europe. Psoriatic arthritis (PsA) is closely associated to Pso whereas the…
Abstract Number: 2467 • 2019 ACR/ARP Annual Meeting
Pain and Anxiety Are Independent Factors Associated to Sleep Impairment in Psoriatic Arthritis: A Multicentric Study in 14 Countries
Penelope Palominos¹, Laura Coates ², Charles Kohem ³, Ana-Maria Orbai ⁴, Josef Smolen ⁵, Maarten de Wit ⁶, Uta Kiltz ⁷, Ying-Ying Leung ⁸, Juan Cañete ⁹, Rossana Scrivo ¹⁰, Andra Balanescu ¹¹, Emmanuelle Dernis ¹², Sandra Talli ¹³, Martin SOUBRIER ¹⁴, Sibel Zehra Aydin ¹⁵, Inna Gaydukova ¹⁶, Umut Kalyoncu ¹⁷ and Laure Gossec ¹⁸, ¹Serviço de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul,, Porto Alegra, Brazil, ²University of Oxford, Oxford, United Kingdom, ³Serviço de Reumatologia, Hospital de Clinicas de Porto Alegre, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, Baltimore Maryland, ⁵Medical University of Vienna, Vienna, Austria, ⁶Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, ⁷Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ⁸Department of Rheumatology and Immunology, Singapore General Hospital,, Singapore, Singapore, ⁹Department of Rheumatology, Hospital Clínic, Barcelona, Barcelona, Spain, ¹⁰Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza Università di Roma,, Rome, Italy, ¹¹Sf Maria Hospital, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania, ¹²Rheumatology Department, Le Mans Central Hospital, Le Mans, France, ¹³Rheumatology Department, East-Tallinn Central Hospital, Tallinn, Estonia, ¹⁴CHU Gabriel Montpied, Clermont Ferrand, Auvergne, France, ¹⁵University of Ottawa Faculty of Medicine, Rheumatology,Ottawa Hospital Research Institute, 1967 Riverside Drive, Ottawa, ON, K1H 7W9, CANADA, Ottawa, Canada, ¹⁶North-western State medical university, St Petersburg, Russia, ¹⁷Hacettepe University Department of Rheumatology, Ankara, Turkey, ¹⁸Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France
Background/Purpose: Sleep quality is diminished in patients with psoriatic arthritis (PsA) and close to 40% of PsA patients consider sleep impairment a priority domain.This work…
Abstract Number: 2488 • 2019 ACR/ARP Annual Meeting
MDA Versus DAPSA: Applicability in a Real World
rafaela Gonçalves¹, Lays Martins ², henrique mariz ¹, marina brito ³, georgia pereira ³, andrea dantas ³ and Angela Duarte ², ¹clinical hospital of federal university of pernambuco, recife, Pernambuco, Brazil, ²Universidade Federal de Pernambuco, Recife, Brazil, ³clinical hospital of federal university of pernambuco, recife, Brazil
Background/Purpose: Background/Purpose: Psoriatic arthritis (PsA) is a progressive, chronic, and potentially irreversible inflammatory disorder. Systematic clinical follow-up of PsA patients is necessary to maintain and…
Abstract Number: 2511 • 2019 ACR/ARP Annual Meeting
What Influences Patients’ Opinion of Remission and Low Disease Activity in Psoriatic Arthritis? Principal Component Analysis of an International Study
Laura Coates¹, Danielle Robinson ², Ana-Maria Orbai ³, Uta Kiltz ⁴, Ying-Ying Leung ⁵, Penelope Palominos ⁶, Juan Cañete ⁷, Rossana Scrivo ⁸, Andra Balanescu ⁹, Emmanuelle Dernis ¹⁰, Sandra Talli ¹¹, Adeline Ruyssen-Witrand ¹², Lihi Eder ¹³, Maarten de Wit ¹⁴, Josef Smolen ¹⁵, Ennio Lubrano ¹⁶ and Laure Gossec ¹⁷, ¹University of Oxford, Oxford, United Kingdom, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ⁵Department of Rheumatology and Immunology, Singapore General Hospital,, Singapore, Singapore, ⁶Serviço de Reumatologia, Hospital de Clínicas de Porto Alegre, Universidade Federal do Rio Grande do Sul,, Porto Alegra, Brazil, ⁷Rheumatology Department, Hospital Clínic and IDIBAPS,, Barcelona, Spain, ⁸Rheumatology Unit, Department of Internal Medicine and Medical Specialties, Sapienza Università di Roma,, Rome, Italy, ⁹Sf Maria Hospital, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania, ¹⁰Rheumatology Department, Le Mans Central Hospital, Le Mans, France, ¹¹Rheumatology Department, East-Tallinn Central Hospital, Tallinn, Estonia, ¹²Rheumatology Unit, Toulouse university Hospital, UMR 1027, Inserm, Université Paul Sabatier Toulouse III, Toulouse, France, ¹³Women’s College Hospital and the Department of Medicine, University of Toronto, Toronto, Canada, ¹⁴Department of Medical Humanities, Amsterdam Public Health (APH), Amsterdam University Medical Centre, Amsterdam, Netherlands, ¹⁵Medical University of Vienna, Vienna, Austria, ¹⁶15. Academic Rheumatology Unit, Dipartimento di Medicina e Scienze della Salute ’Vincenzo Tiberio’, University of Molise, Campobasso, Italy, ¹⁷Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: In psoriatic arthritis (PsA), the objective of treatment is remission or low disease activity (LDA), but there is little research into patients’ perception of…
Abstract Number: 2880 • 2019 ACR/ARP Annual Meeting
Secukinumab Improves Axial Manifestations in Patients with Psoriatic Arthritis and Inadequate Response to NSAIDs: Primary Analysis of Phase 3 Trial
Xenofon Baraliakos¹, Laura Coates ², Laure Gossec ³, Slawomir Jeka ⁴, Antonio Mera ⁵, Barbara Schulz ⁶, Michael Rissler ⁶, Ayan Das Gupta ⁷, Chiara Perella ⁶ and Effie Pournara ⁸, ¹Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany, ²University of Oxford, Oxford, United Kingdom, ³Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France, ⁴University Hospital Bydgoszcz no 2, CM UMK, Bydgoszcz, Poland, ⁵Division of Rheumatology, Instituto de Investigación Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, Santiago de Compostela, Spain, ⁶Novartis Pharma AG, Basel, Switzerland, ⁷Novartis Healthcare Pvt Ltd, Hyderabad, India, ⁸Novartis Pharma AG, Basel, Basel-Stadt, Switzerland
Background/Purpose: Secukinumab (SEC) has provided significant and sustained improvement in the signs and symptoms of active psoriatic arthritis (PsA) and ankylosing spondylitis1. Evidence is limited…
Abstract Number: 291 • 2019 ACR/ARP Annual Meeting
Factors Explaining Patient Perspective in Psoriasis and Psoriatic Arthritis: The Role of Inflammation and Structural Damage Detected by Ultrasound
Tania Gudu¹, Ilaria Padovano ¹, Hélène Gouze ², François Vidal ¹, Emmanuel Mahé ³, Leire Lara Gonzalez ⁴, Alexis Guyot ⁴, Philippe Saiag ⁴, Isabelle Bourgault Villada ⁴, Sophie Ruel-Gagné ¹, Gilles Hayem ¹, Félicie Costantino ⁵, Maxime Breban ⁶ and Maria-Antonietta D’Agostino ⁷, ¹Rheumatology Department, APHP, Ambroise Paré Hospital, Boulogne Billancourt, France, ²Rheumatology Department, APHP, Ambroise Paré Hospital, Bolougne Billancourt, France, ³Dermatology Department, Victor Dupouy Hospital, Argenteuil, France, ⁴Dermatology Department, Ambroise Paré Hospital, Boulogne Billancourt, France, ⁵UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne-Billancourt, France, Boulogne Billancourt, France, ⁶UMR1173, INSERM/Versailles-Saint Quentin University, France Ambroise Paré Hospital (AP-HP) Department of Rheumatology, Boulogne-Billancourt, France, Boulogne Billancourt, ⁷Department of Rheumatology, APHP, Hôpital Ambroise Paré, Paris, France
Background/Purpose: Patient reported outcomes (PROs) reflect patients’ opinion on disease activity, impact of disease, quality of life (QoL), disability and are essential in the assessment…
Abstract Number: 1009 • 2019 ACR/ARP Annual Meeting
PDE4 Inhibition Could Improve Endothelial and Adipose Tissue Dysfunction Associated with Psoriatic Arthritis, Key Processes in Cardiovascular Disease
Ivan Arias de la Rosa¹, Carmen Torres-Granados ¹, Maria del Carmen Abalos-Aguilera ², Ignacio Gomez-Garcia ², Rocio Guzman-Ruiz ³, Maria del Mar Malagon ³, Carlos Perez-Sanchez ⁴, Alejandra Patiño-Trives ², Maria Luque-Tevar ², Alejandro Ibañez-Costa ², Alejandro Escudero ⁵, Eduardo Collantes-Estevez ¹, Chary Lopez-Pedrera ², Maria Dolores Lopez-Montilla ² and Nuria Barbarroja ³, ¹University of Cordoba/IMIBIC/Reina Sofia Hospital, Cordoba, Spain, ²IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, ³University of Cordoba/IMIBIC/Reina Sofia Hospital and CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III, Cordoba, Spain, ⁴Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, Cordoba, Spain, ⁵IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain
Background/Purpose: Psoriatic arthritis (PsA) is the rheumatic disease most associated with metabolic disorders, including obesity and metabolic syndrome, where inflammation is a determinant key factor,…
Abstract Number: 1211 • 2019 ACR/ARP Annual Meeting
Improving Exercise Counselling of Patients with Inflammatory Arthritis: A Quality Improvement Project
Anwar Albasri ¹, Tariq Al-Araimi ¹, Stephanie Gottheil¹, Lauren King ¹, Sahil Koppikar ², Justin Shamis ¹, Shirley Lake ³ and Gakhal Natasha ¹, ¹University of Toronto, Toronto, Canada, ²University of Toronto, Markham, ON, Canada, ³Division of Rheumatology, Sunnybrook Hospital, Toronto, ON, Canada
Background/Purpose: Regular aerobic exercise has been shown to improve inflammatory arthritis (IA) symptoms and may reduce the risk of cardiovascular events observed in these patients.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].